Plus   Neg

Wipro Appoints Capgemini Executive Thierry Delaporte As CEO - Quick Facts

Wipro Limited (WIT), an information technology, consulting and business process services company, said Friday that it has appointed Thierry Delaporte as its Chief Executive Officer and Managing Director, effective July 6, 2020. He will be based in Paris and report to Chairman Rishad Premji.

Most recently, Thierry Delaporte was the Chief Operating Officer of Capgemini Group and a member of its Group Executive Board. During his twenty-five year career with Capgemini, he held several leadership roles including that of Chief Executive Officer of the Global Financial Services Strategic Business Unit, and head of all global service lines.

Wipro also said that Abidali Neemuchwala will relinquish his position as Chief Executive Officer and MD on June 1. The company's founder Azim Premji's son Rishad Premji will oversee the day to day operations of the company until July 5.

In addition, Wipro noted that it appointed Deepak Satwalekar to its Board for five years effective July 1, 2020, subject to the approval of the shareholders. Deepak will serve as an Independent Director on the Board.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT